Clinical Trial

Objective Study on Tongue Diagnosis of Chronic Atrophic Gastritis

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Chronic atrophic gastritis with intestinal metaplasia or dysplasia is called precancerous lesions of gastric cancer ( PLGC ). It is an important stage in the transformation of normal mucosa to gastric cancer and is significantly associated with the risk of gastric cancer. Early identification of PLGC high-risk groups is the focus of prevention and treatment of gastric cancer. Gastroscopy and pathological examination are the key means to diagnose PLGC. However, due to the invasiveness, high cost, strong professional operability and traumatic pathological sampling, the application of gastroscopy is greatly limited, and the predictive significance of serum markers for the occurrence and prognosis of PLGC is limited. The current PLGC monitoring methods are not targeted enough, and there is still a lack of effective risk prediction models for PLGC. New screening methods are needed to improve the early diagnosis rate of PLGC. Tongue diagnosis is simple, convenient, easy and inexpensive. It can dynamically monitor the risk of PLGC in patients with chronic atrophic gastritis in early real time, and timely formulate individualized intervention measures, which is of great significance for improving the prognosis of patients, controlling medical expenses and truncating disease progression. Based on the objectification of tongue diagnosis, it may become an important method for screening PLGC from the perspective of macroscopic tongue image characteristics and microscopic tongue coating flora.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06489132
Lead Sponsor Peking University First Hospital
Conditions Chronic Atrophic Gastritis
Enrollment 498 participants
Start Date 2024-07
Primary Completion 2026-02 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2024-07-05